IL133420A - Tablet-shaped pharmaceutical preparation containing a combination of piperidinoalkanol and antihistamines and reduces symptomatic congestion - Google Patents

Tablet-shaped pharmaceutical preparation containing a combination of piperidinoalkanol and antihistamines and reduces symptomatic congestion

Info

Publication number: IL133420A
Authority: IL; Israel
Prior art keywords: formulation; amount; weight; pharmaceutical composition; carrier base
Prior art date: 1997-08-26

Application number

IL13342098A

Other languages

English (en)

Hebrew (he)

Other versions

IL133420A0 (en

Original Assignee

Aventis Pharma Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-08-26

Filing date

1998-07-21

Publication date

2004-07-25

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25443270&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL133420(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1998-07-21 Application filed by Aventis Pharma Inc filed Critical Aventis Pharma Inc

2001-04-30 Publication of IL133420A0 publication Critical patent/IL133420A0/xx

2004-07-25 Publication of IL133420A publication Critical patent/IL133420A/en

Links

239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 38
229940127230 sympathomimetic drug Drugs 0.000 title claims abstract description 34
239000000739 antihistaminic agent Substances 0.000 title claims abstract description 21
230000001387 anti-histamine Effects 0.000 title claims abstract description 18
239000000850 decongestant Substances 0.000 title claims abstract description 17
239000000203 mixture Substances 0.000 claims abstract description 157
238000009472 formulation Methods 0.000 claims abstract description 97
239000000463 material Substances 0.000 claims abstract description 34
150000003839 salts Chemical class 0.000 claims abstract description 30
239000012729 immediate-release (IR) formulation Substances 0.000 claims abstract description 16
239000012730 sustained-release form Substances 0.000 claims abstract description 16
239000003085 diluting agent Substances 0.000 claims abstract description 15
229920000881 Modified starch Polymers 0.000 claims abstract description 14
238000013268 sustained release Methods 0.000 claims abstract description 14
229920002678 cellulose Polymers 0.000 claims abstract description 13
239000001913 cellulose Substances 0.000 claims abstract description 13
239000007884 disintegrant Substances 0.000 claims abstract description 11
239000000314 lubricant Substances 0.000 claims abstract description 11
230000000181 anti-adherent effect Effects 0.000 claims abstract description 9
239000003911 antiadherent Substances 0.000 claims abstract description 9
239000004203 carnauba wax Substances 0.000 claims abstract description 5
235000013869 carnauba wax Nutrition 0.000 claims abstract description 5
KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 claims description 58
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 47
239000001993 wax Substances 0.000 claims description 35
BALXUFOVQVENIU-KXNXZCPBSA-N pseudoephedrine hydrochloride Chemical compound [H+].[Cl-].CN[C@@H](C)[C@@H](O)C1=CC=CC=C1 BALXUFOVQVENIU-KXNXZCPBSA-N 0.000 claims description 22
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical group [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 18
229960003447 pseudoephedrine hydrochloride Drugs 0.000 claims description 17
239000011248 coating agent Substances 0.000 claims description 16
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical group O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 15
229920002785 Croscarmellose sodium Polymers 0.000 claims description 11
235000021355 Stearic acid Nutrition 0.000 claims description 11
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical group [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 11
229960001681 croscarmellose sodium Drugs 0.000 claims description 11
235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims description 11
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 11
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 11
239000008117 stearic acid Substances 0.000 claims description 11
229920003084 Avicel® PH-102 Polymers 0.000 claims description 10
230000003287 optical effect Effects 0.000 claims description 10
235000019359 magnesium stearate Nutrition 0.000 claims description 9
229940075614 colloidal silicon dioxide Drugs 0.000 claims description 8
239000003826 tablet Substances 0.000 description 91
238000005469 granulation Methods 0.000 description 52
230000003179 granulation Effects 0.000 description 52
229960003908 pseudoephedrine Drugs 0.000 description 41
KWGRBVOPPLSCSI-WCBMZHEXSA-N pseudoephedrine Chemical compound CN[C@@H](C)[C@@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WCBMZHEXSA-N 0.000 description 41
238000000034 method Methods 0.000 description 38
150000001875 compounds Chemical class 0.000 description 33
239000010410 layer Substances 0.000 description 29
239000002585 base Substances 0.000 description 23
230000008569 process Effects 0.000 description 20
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 17
238000000576 coating method Methods 0.000 description 16
238000002156 mixing Methods 0.000 description 15
-1 piperidino, morpholino Chemical group 0.000 description 14
238000007906 compression Methods 0.000 description 13
238000004090 dissolution Methods 0.000 description 13
238000004519 manufacturing process Methods 0.000 description 13
230000006835 compression Effects 0.000 description 11
239000001257 hydrogen Substances 0.000 description 11
229910052739 hydrogen Inorganic materials 0.000 description 11
125000004432 carbon atom Chemical group C* 0.000 description 10
239000003814 drug Substances 0.000 description 10
239000007788 liquid Substances 0.000 description 10
229910001220 stainless steel Inorganic materials 0.000 description 10
239000010935 stainless steel Substances 0.000 description 10
235000019813 microcrystalline cellulose Nutrition 0.000 description 9
239000008108 microcrystalline cellulose Substances 0.000 description 9
229940016286 microcrystalline cellulose Drugs 0.000 description 9
229920000168 Microcrystalline cellulose Polymers 0.000 description 8
235000010980 cellulose Nutrition 0.000 description 8
239000000243 solution Substances 0.000 description 8
239000000150 Sympathomimetic Substances 0.000 description 7
125000004435 hydrogen atom Chemical group [H]* 0.000 description 7
239000002245 particle Substances 0.000 description 7
239000000725 suspension Substances 0.000 description 7
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
239000002253 acid Substances 0.000 description 6
239000002775 capsule Substances 0.000 description 6
238000001035 drying Methods 0.000 description 6
239000000047 product Substances 0.000 description 6
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 5
239000004698 Polyethylene Substances 0.000 description 5
239000012530 fluid Substances 0.000 description 5
238000004128 high performance liquid chromatography Methods 0.000 description 5
125000002887 hydroxy group Chemical group [H]O* 0.000 description 5
239000007942 layered tablet Substances 0.000 description 5
238000003801 milling Methods 0.000 description 5
229920000573 polyethylene Polymers 0.000 description 5
229920000036 polyvinylpyrrolidone Polymers 0.000 description 5
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 5
239000012488 sample solution Substances 0.000 description 5
239000000454 talc Substances 0.000 description 5
229910052623 talc Inorganic materials 0.000 description 5
235000012222 talc Nutrition 0.000 description 5
GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 4
125000000217 alkyl group Chemical group 0.000 description 4
229940008201 allegra Drugs 0.000 description 4
RWTNPBWLLIMQHL-UHFFFAOYSA-N fexofenadine Chemical compound C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RWTNPBWLLIMQHL-UHFFFAOYSA-N 0.000 description 4
239000000835 fiber Substances 0.000 description 4
239000012458 free base Substances 0.000 description 4
239000004615 ingredient Substances 0.000 description 4
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 4
235000010603 pastilles Nutrition 0.000 description 4
239000000546 pharmaceutical excipient Substances 0.000 description 4
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 4
238000011020 pilot scale process Methods 0.000 description 4
239000001267 polyvinylpyrrolidone Substances 0.000 description 4
238000000527 sonication Methods 0.000 description 4
239000007921 spray Substances 0.000 description 4
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 3
WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 3
206010028735 Nasal congestion Diseases 0.000 description 3
229920002472 Starch Polymers 0.000 description 3
208000024780 Urticaria Diseases 0.000 description 3
239000000043 antiallergic agent Substances 0.000 description 3
229940125715 antihistaminic agent Drugs 0.000 description 3
239000003963 antioxidant agent Substances 0.000 description 3
235000006708 antioxidants Nutrition 0.000 description 3
229940124630 bronchodilator Drugs 0.000 description 3
238000005336 cracking Methods 0.000 description 3
239000002552 dosage form Substances 0.000 description 3
229960001680 ibuprofen Drugs 0.000 description 3
229940060367 inert ingredients Drugs 0.000 description 3
239000000523 sample Substances 0.000 description 3
239000000377 silicon dioxide Substances 0.000 description 3
235000012239 silicon dioxide Nutrition 0.000 description 3
229910052708 sodium Inorganic materials 0.000 description 3
239000011734 sodium Substances 0.000 description 3
239000008107 starch Substances 0.000 description 3
229940032147 starch Drugs 0.000 description 3
235000019698 starch Nutrition 0.000 description 3
229940015297 1-octanesulfonic acid Drugs 0.000 description 2
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
241000124008 Mammalia Species 0.000 description 2
CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 2
GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
239000002202 Polyethylene glycol Substances 0.000 description 2
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
238000010521 absorption reaction Methods 0.000 description 2
235000010443 alginic acid Nutrition 0.000 description 2
239000000783 alginic acid Substances 0.000 description 2
229920000615 alginic acid Polymers 0.000 description 2
229960001126 alginic acid Drugs 0.000 description 2
150000004781 alginic acids Chemical class 0.000 description 2
125000003545 alkoxy group Chemical group 0.000 description 2
150000001412 amines Chemical class 0.000 description 2
239000011230 binding agent Substances 0.000 description 2
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical compound BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
239000000168 bronchodilator agent Substances 0.000 description 2
239000000872 buffer Substances 0.000 description 2
CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 2
239000008116 calcium stearate Substances 0.000 description 2
235000013539 calcium stearate Nutrition 0.000 description 2
238000005341 cation exchange Methods 0.000 description 2
238000006243 chemical reaction Methods 0.000 description 2
239000003086 colorant Substances 0.000 description 2
239000007891 compressed tablet Substances 0.000 description 2
238000001816 cooling Methods 0.000 description 2
229960000913 crospovidone Drugs 0.000 description 2
PAFZNILMFXTMIY-UHFFFAOYSA-N cyclohexylamine Chemical compound NC1CCCCC1 PAFZNILMFXTMIY-UHFFFAOYSA-N 0.000 description 2
DLNKOYKMWOXYQA-UHFFFAOYSA-N dl-pseudophenylpropanolamine Natural products CC(N)C(O)C1=CC=CC=C1 DLNKOYKMWOXYQA-UHFFFAOYSA-N 0.000 description 2
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
239000007941 film coated tablet Substances 0.000 description 2
239000012467 final product Substances 0.000 description 2
239000000796 flavoring agent Substances 0.000 description 2
235000013355 food flavoring agent Nutrition 0.000 description 2
235000003599 food sweetener Nutrition 0.000 description 2
125000005843 halogen group Chemical group 0.000 description 2
238000010438 heat treatment Methods 0.000 description 2
BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
239000008172 hydrogenated vegetable oil Substances 0.000 description 2
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
238000002347 injection Methods 0.000 description 2
239000007924 injection Substances 0.000 description 2
SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 2
125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
229940057948 magnesium stearate Drugs 0.000 description 2
239000011159 matrix material Substances 0.000 description 2
239000000155 melt Substances 0.000 description 2
150000007522 mineralic acids Chemical class 0.000 description 2
WUOSYUHCXLQPQJ-UHFFFAOYSA-N n-(3-chlorophenyl)-n-methylacetamide Chemical class CC(=O)N(C)C1=CC=CC(Cl)=C1 WUOSYUHCXLQPQJ-UHFFFAOYSA-N 0.000 description 2
125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
150000007524 organic acids Chemical class 0.000 description 2
SONNWYBIRXJNDC-VIFPVBQESA-N phenylephrine Chemical compound CNC[C@H](O)C1=CC=CC(O)=C1 SONNWYBIRXJNDC-VIFPVBQESA-N 0.000 description 2
229960001802 phenylephrine Drugs 0.000 description 2
229960000395 phenylpropanolamine Drugs 0.000 description 2
DLNKOYKMWOXYQA-APPZFPTMSA-N phenylpropanolamine Chemical compound C[C@@H](N)[C@H](O)C1=CC=CC=C1 DLNKOYKMWOXYQA-APPZFPTMSA-N 0.000 description 2
229960000540 polacrilin potassium Drugs 0.000 description 2
229920001223 polyethylene glycol Polymers 0.000 description 2
235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 2
229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 2
WVWZXTJUCNEUAE-UHFFFAOYSA-M potassium;1,2-bis(ethenyl)benzene;2-methylprop-2-enoate Chemical compound [K+].CC(=C)C([O-])=O.C=CC1=CC=CC=C1C=C WVWZXTJUCNEUAE-UHFFFAOYSA-M 0.000 description 2
239000000843 powder Substances 0.000 description 2
238000012545 processing Methods 0.000 description 2
230000002035 prolonged effect Effects 0.000 description 2
239000008213 purified water Substances 0.000 description 2
238000005070 sampling Methods 0.000 description 2
239000001632 sodium acetate Substances 0.000 description 2
235000017281 sodium acetate Nutrition 0.000 description 2
229920003109 sodium starch glycolate Polymers 0.000 description 2
229940079832 sodium starch glycolate Drugs 0.000 description 2
239000008109 sodium starch glycolate Substances 0.000 description 2
239000007892 solid unit dosage form Substances 0.000 description 2
238000005507 spraying Methods 0.000 description 2
239000003765 sweetening agent Substances 0.000 description 2
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
229940124597 therapeutic agent Drugs 0.000 description 2
230000004797 therapeutic response Effects 0.000 description 2
238000000825 ultraviolet detection Methods 0.000 description 2
XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 2
QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
QXQAPNSHUJORMC-UHFFFAOYSA-N 1-chloro-4-propylbenzene Chemical compound CCCC1=CC=C(Cl)C=C1 QXQAPNSHUJORMC-UHFFFAOYSA-N 0.000 description 1
IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
PKRSYEPBQPFNRB-UHFFFAOYSA-N 2-phenoxybenzoic acid Chemical compound OC(=O)C1=CC=CC=C1OC1=CC=CC=C1 PKRSYEPBQPFNRB-UHFFFAOYSA-N 0.000 description 1
QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
WUBBRNOQWQTFEX-UHFFFAOYSA-N 4-aminosalicylic acid Chemical compound NC1=CC=C(C(O)=O)C(O)=C1 WUBBRNOQWQTFEX-UHFFFAOYSA-N 0.000 description 1
125000005274 4-hydroxybenzoic acid group Chemical group 0.000 description 1
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
241000282472 Canis lupus familiaris Species 0.000 description 1
KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 1
WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
241000282412 Homo Species 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
239000004166 Lanolin Substances 0.000 description 1
WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
OPKOKAMJFNKNAS-UHFFFAOYSA-N N-methylethanolamine Chemical compound CNCCO OPKOKAMJFNKNAS-UHFFFAOYSA-N 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
241000700159 Rattus Species 0.000 description 1
206010039085 Rhinitis allergic Diseases 0.000 description 1
208000036284 Rhinitis seasonal Diseases 0.000 description 1
206010040744 Sinus headache Diseases 0.000 description 1
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
239000008186 active pharmaceutical agent Substances 0.000 description 1
229910052783 alkali metal Inorganic materials 0.000 description 1
150000001340 alkali metals Chemical class 0.000 description 1
229910052784 alkaline earth metal Inorganic materials 0.000 description 1
150000001342 alkaline earth metals Chemical class 0.000 description 1
125000003282 alkyl amino group Chemical group 0.000 description 1
201000010105 allergic rhinitis Diseases 0.000 description 1
229910052782 aluminium Inorganic materials 0.000 description 1
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
230000003266 anti-allergic effect Effects 0.000 description 1
125000004429 atom Chemical group 0.000 description 1
239000011324 bead Substances 0.000 description 1
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
238000009835 boiling Methods 0.000 description 1
229910052794 bromium Inorganic materials 0.000 description 1
230000003182 bronchodilatating effect Effects 0.000 description 1
239000011575 calcium Substances 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
229910000019 calcium carbonate Inorganic materials 0.000 description 1
229960003563 calcium carbonate Drugs 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
150000005323 carbonate salts Chemical class 0.000 description 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
150000001735 carboxylic acids Chemical class 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
239000003093 cationic surfactant Substances 0.000 description 1
229960000541 cetyl alcohol Drugs 0.000 description 1
238000002144 chemical decomposition reaction Methods 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
239000000460 chlorine Substances 0.000 description 1
229910052801 chlorine Inorganic materials 0.000 description 1
229940124301 concurrent medication Drugs 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
239000000498 cooling water Substances 0.000 description 1
125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
238000000354 decomposition reaction Methods 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
150000004683 dihydrates Chemical class 0.000 description 1
238000006073 displacement reaction Methods 0.000 description 1
238000011978 dissolution method Methods 0.000 description 1
238000007922 dissolution test Methods 0.000 description 1
229940079593 drug Drugs 0.000 description 1
238000009506 drug dissolution testing Methods 0.000 description 1
229940088679 drug related substance Drugs 0.000 description 1
230000000694 effects Effects 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
238000001914 filtration Methods 0.000 description 1
229910052731 fluorine Inorganic materials 0.000 description 1
239000011737 fluorine Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
235000011187 glycerol Nutrition 0.000 description 1
150000004820 halides Chemical class 0.000 description 1
229910052736 halogen Inorganic materials 0.000 description 1
150000002367 halogens Chemical class 0.000 description 1
230000036541 health Effects 0.000 description 1
125000000623 heterocyclic group Chemical group 0.000 description 1
UWYVPFMHMJIBHE-OWOJBTEDSA-N hydroxymaleic acid group Chemical group O/C(/C(=O)O)=C/C(=O)O UWYVPFMHMJIBHE-OWOJBTEDSA-N 0.000 description 1
150000007529 inorganic bases Chemical class 0.000 description 1
229910052740 iodine Inorganic materials 0.000 description 1
239000008101 lactose Substances 0.000 description 1
229960001375 lactose Drugs 0.000 description 1
235000019388 lanolin Nutrition 0.000 description 1
229940039717 lanolin Drugs 0.000 description 1
229910052744 lithium Inorganic materials 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
229960002510 mandelic acid Drugs 0.000 description 1
238000005259 measurement Methods 0.000 description 1
238000002483 medication Methods 0.000 description 1
238000002844 melting Methods 0.000 description 1
230000008018 melting Effects 0.000 description 1
QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
229910052753 mercury Inorganic materials 0.000 description 1
229910052751 metal Inorganic materials 0.000 description 1
239000002184 metal Substances 0.000 description 1
150000002739 metals Chemical class 0.000 description 1
229940063559 methacrylic acid Drugs 0.000 description 1
239000002480 mineral oil Substances 0.000 description 1
235000010446 mineral oil Nutrition 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
125000002950 monocyclic group Chemical group 0.000 description 1
GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
201000009240 nasopharyngitis Diseases 0.000 description 1
239000002736 nonionic surfactant Substances 0.000 description 1
239000006186 oral dosage form Substances 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
150000007530 organic bases Chemical class 0.000 description 1
239000012188 paraffin wax Substances 0.000 description 1
229940124531 pharmaceutical excipient Drugs 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
235000011007 phosphoric acid Nutrition 0.000 description 1
150000003016 phosphoric acids Chemical class 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
239000011591 potassium Substances 0.000 description 1
229940069328 povidone Drugs 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
150000003141 primary amines Chemical class 0.000 description 1
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
230000009467 reduction Effects 0.000 description 1
230000004044 response Effects 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
150000003335 secondary amines Chemical class 0.000 description 1
239000002356 single layer Substances 0.000 description 1
201000009890 sinusitis Diseases 0.000 description 1
235000010413 sodium alginate Nutrition 0.000 description 1
239000000661 sodium alginate Substances 0.000 description 1
229940005550 sodium alginate Drugs 0.000 description 1
229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
235000017557 sodium bicarbonate Nutrition 0.000 description 1
239000001488 sodium phosphate Substances 0.000 description 1
229910000162 sodium phosphate Inorganic materials 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000002904 solvent Substances 0.000 description 1
241000894007 species Species 0.000 description 1
239000007858 starting material Substances 0.000 description 1
238000003756 stirring Methods 0.000 description 1
125000001424 substituent group Chemical group 0.000 description 1
229940089453 sudafed Drugs 0.000 description 1
150000003460 sulfonic acids Chemical class 0.000 description 1
230000001975 sympathomimetic effect Effects 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
239000011975 tartaric acid Substances 0.000 description 1
235000002906 tartaric acid Nutrition 0.000 description 1
150000003512 tertiary amines Chemical class 0.000 description 1
239000012085 test solution Substances 0.000 description 1
238000012360 testing method Methods 0.000 description 1
125000001544 thienyl group Chemical group 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
239000002699 waste material Substances 0.000 description 1
229940045860 white wax Drugs 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Epidemiology (AREA)
Pulmonology (AREA)
Virology (AREA)
Molecular Biology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Otolaryngology (AREA)
Immunology (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

IL13342098A 1997-08-26 1998-07-21 Tablet-shaped pharmaceutical preparation containing a combination of piperidinoalkanol and antihistamines and reduces symptomatic congestion IL133420A (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US92015897A	1997-08-26	1997-08-26
PCT/US1998/015237 WO1999009957A1 (en)	1997-08-26	1998-07-21	Pharmaceutical composition for combination of piperidinoalkanol-decongestant

Publications (2)

Publication Number	Publication Date
IL133420A0 IL133420A0 (en)	2001-04-30
IL133420A true IL133420A (en)	2004-07-25

Family

ID=25443270

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IL13342098A IL133420A (en)	1997-08-26	1998-07-21	Tablet-shaped pharmaceutical preparation containing a combination of piperidinoalkanol and antihistamines and reduces symptomatic congestion

Country Status (30)

Country	Link
US (1)	US6039974A (pl)
EP (1)	EP0998272B1 (pl)
JP (1)	JP4344405B2 (pl)
KR (1)	KR100514264B1 (pl)
CN (1)	CN1159012C (pl)
AR (1)	AR013947A1 (pl)
AT (1)	ATE238773T1 (pl)
AU (1)	AU725811B2 (pl)
BR (1)	BR9812001A (pl)
CZ (1)	CZ295461B6 (pl)
DE (1)	DE69814086T2 (pl)
DK (1)	DK0998272T3 (pl)
EE (1)	EE04294B1 (pl)
ES (1)	ES2192781T3 (pl)
HU (1)	HU224921B1 (pl)
ID (1)	ID22891A (pl)
IL (1)	IL133420A (pl)
NO (1)	NO318246B1 (pl)
NZ (1)	NZ501248A (pl)
OA (1)	OA11285A (pl)
PL (1)	PL192079B1 (pl)
PT (1)	PT998272E (pl)
RU (1)	RU2207879C2 (pl)
SI (1)	SI0998272T1 (pl)
SK (1)	SK283803B6 (pl)
TR (1)	TR200000517T2 (pl)
TW (1)	TW570812B (pl)
UA (1)	UA60335C2 (pl)
WO (1)	WO1999009957A1 (pl)
ZA (1)	ZA987552B (pl)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2449419C (en) *	1994-05-18	2011-09-06	Aventis Pharmaceuticals Inc.	Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudomorphs thereof
US20030045722A1 (en) *	1994-05-18	2003-03-06	Henton Daniel R.	Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudomorphs thereof
EP0812195B1 (en)	1995-02-28	2002-10-30	Aventis Pharmaceuticals Inc.	Pharmaceutical composition for piperidinoalkanol compounds
US8022095B2 (en)	1996-08-16	2011-09-20	Pozen, Inc.	Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs
WO2001045676A2 (en) *	1999-12-20	2001-06-28	Schering Corporation	Extended release oral dosage composition
US20020094345A1 (en)	2000-10-06	2002-07-18	Sara Abelaira	Pharmaceutical compositions containing epinastine and pseudoephedrine
AU2002220248A1 (en) *	2000-11-06	2002-05-15	Andrx Pharmaceuticals, Inc.	Once a day antihistamine and decongestant formulation
FR2818552B1 (fr) *	2000-12-26	2003-02-07	Servier Lab	Compositions pharmaceutique solide thermoformable pour la liberation controlee d'ivabradine
US20030021849A1 (en) *	2001-04-09	2003-01-30	Ben-Zion Dolitzky	Polymorphs of fexofenadine hydrochloride
CZ20033019A3 (cs) *	2001-04-09	2004-07-14	Teva Pharmaceutical Industries Ltd.	Polymorfní formy chloridu fexofenadinu
US7052706B2 (en) *	2001-06-08	2006-05-30	Nostrum Pharmaceuticals, Inc.	Control release formulation containing a hydrophobic material as the sustained release agent
US6863901B2 (en)	2001-11-30	2005-03-08	Collegium Pharmaceutical, Inc.	Pharmaceutical composition for compressed annular tablet with molded triturate tablet for both intraoral and oral administration
US6827946B2 (en)	2001-12-05	2004-12-07	Collegium Pharmaceutical, Inc.	Compositions containing both sedative and non-sedative antihistamines
DE60220953T2 (de) *	2002-04-04	2008-02-28	Dr. Reddy's Laboratories Ltd.	Pharmazeutische zusammensetzungen enthaltend eine antihistaminische abschwellende arzneistoffkombination und ein verfahren zur herstellung davon
EP1474392A1 (en) *	2002-06-10	2004-11-10	Teva Pharmaceutical Industries Ltd.	Polymorphic form xvi of fexofenadine hydrochloride
US6663892B1 (en)	2002-08-19	2003-12-16	L. Perrigo Company	Multiple portion tablet
US20050152967A1 (en) *	2003-03-28	2005-07-14	Pfab, Lp	Dynamic variable release
EP1715856B1 (en) *	2003-12-31	2012-07-11	Actavis Group PTC ehf.	Atomoxetine formulations
US20050220877A1 (en) *	2004-03-31	2005-10-06	Patel Ashish A	Bilayer tablet comprising an antihistamine and a decongestant
KR20070007196A (ko) *	2004-04-26	2007-01-12	테바 파마슈티컬 인더스트리즈 리미티드	펙소페나딘 히드로클로라이드의 결정형 및 이의 제조 방법
CN101891680B (zh)	2004-06-24	2014-10-29	沃泰克斯药物股份有限公司	Atp-结合弹夹转运蛋白的调控剂
JP2008514641A (ja) *	2004-09-28	2008-05-08	テバファーマシューティカルインダストリーズリミティド	結晶形フェキソフェナジン、およびその調製方法
US20080095846A1 (en) *	2004-11-04	2008-04-24	Gour Mukherji	Pharmaceutical compositions of antihistamine and decongestant
EP1858483A4 (en) *	2005-03-16	2009-07-15	Reddys Lab Ltd Dr	SYSTEM FOR THE DELIVERY OF MULTIPLE MEDICAMENTS
DK3219705T3 (da)	2005-12-28	2020-04-14	Vertex Pharma	Farmaceutiske sammensætninger af den amorfe form af n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinolin-3-carboxamid
WO2008005287A1 (en) *	2006-06-30	2008-01-10	Teva Pharmaceutical Industries Ltd.	Pharmaceutical compositions comprising a combination of piperidinoalkanol and decongestant
KR20090037930A (ko) *	2006-07-11	2009-04-16	뮤추얼 파마슈티컬 컴퍼니 아이엔씨.	조절 방출 제형
US20080085311A1 (en) *	2006-10-05	2008-04-10	Tripathi Sanjay S	Antihistamine-decongestant combinations
CL2008000280A1 (es) *	2007-02-01	2008-08-18	Takeda Pharmaceutical	Composicion farmaceutica en forma de comprimido que contiene un granulo que comprende un principio activo que induce facilmente a un problema en la compresion y celulosa microcristalina y un auxiliar de compresion que contiene estearato de magnesio y
EP2120945A1 (en) *	2007-02-28	2009-11-25	Collegium Pharmaceutical, Inc.	Antihistamine combination
WO2008114280A1 (en) *	2007-03-21	2008-09-25	Lupin Limited	Novel reduced dose pharmaceutical compositions of fexofenadine and pseudoephedrine
US20090076080A1 (en) *	2007-09-19	2009-03-19	Protia, Llc	Deuterium-enriched fexofenadine
WO2009117130A2 (en)	2008-03-21	2009-09-24	Mylan Pharmaceuticals, Inc.	Extended release forumulation containing a wax
US12458635B2 (en)	2008-08-13	2025-11-04	Vertex Pharmaceuticals Incorporated	Pharmaceutical composition and administrations thereof
US20100256184A1 (en) *	2008-08-13	2010-10-07	Vertex Pharmaceuticals Incorporated	Pharmaceutical composition and administrations thereof
US20100074949A1 (en) *	2008-08-13	2010-03-25	William Rowe	Pharmaceutical composition and administration thereof
SG171751A1 (en) *	2008-11-19	2011-07-28	Merial Ltd	Compositions comprising an aryl pyrazole and/ or a formamidine methods and uses thereof
KR101727762B1 (ko)	2009-03-20	2017-04-17	버텍스 파마슈티칼스 인코포레이티드	낭성 섬유증 막횡단 전도도 조절자의 조정자의 제조 방법
US20120100221A1 (en)	2009-06-02	2012-04-26	Ranbaxy Laboratories Limited	Pharmaceutical compositions containing a combination of an antihistamine and a decongestant
JP2015511583A (ja)	2012-02-27	2015-04-20	バーテックスファーマシューティカルズインコーポレイテッドＶｅｒｔｅｘＰｈａｒｍａｃｅｕｔｉｃａｌｓＩｎｃｏｒｐｏｒａｔｅｄ	薬学的組成物およびその投与
CN105050708A (zh)	2012-11-14	2015-11-11	格雷斯公司	含有生物活性材料与无序无机氧化物的组合物
US10058542B1 (en)	2014-09-12	2018-08-28	Thioredoxin Systems Ab	Composition comprising selenazol or thiazolone derivatives and silver and method of treatment therewith
CN107250113B (zh)	2014-10-07	2019-03-29	弗特克斯药品有限公司	囊性纤维化跨膜传导调节蛋白的调节剂的共晶
JP2019218313A (ja)	2018-06-21	2019-12-26	沢井製薬株式会社	プソイドエフェドリン又はその薬学的に許容される塩を含有する徐放製剤
KR20240019293A (ko) *	2021-06-07	2024-02-14	알.피.쉐러 테크놀러지즈 엘엘씨	습기 감응성 약학 조성물용 보호 코팅

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3806526A (en) *	1972-01-28	1974-04-23	Richardson Merrell Inc	1-aroylalkyl-4-diphenylmethyl piperidines
US3878217A (en) *	1972-01-28	1975-04-15	Richardson Merrell Inc	Alpha-aryl-4-substituted piperidinoalkanol derivatives
US4060634A (en) *	1973-09-26	1977-11-29	Boehringer Mannheim G.M.B.H.	Rapidly resorbable glibenclamide
DE2348334C2 (de) *	1973-09-26	1982-11-11	Boehringer Mannheim Gmbh, 6800 Mannheim	Neue Zubereitungsform des N-4-[2-(5-Chlor-2-methoxybenzamido)äthyl]- phenyl-sulfonyl-N'-cyclohexylharnstoffs
US3966949A (en) *	1973-10-12	1976-06-29	Richardson-Merrell Inc.	Pharmaceutical compositions and preparing same
FR2408345A1 (fr) *	1976-11-30	1979-06-08	Besins Jean Louis	Nouvelle composition a action anti-conceptionnelle
US4285957A (en) *	1979-04-10	1981-08-25	Richardson-Merrell Inc.	1-Piperidine-alkanol derivatives, pharmaceutical compositions thereof, and method of use thereof
US4285958A (en) *	1979-04-10	1981-08-25	Richardson-Merrell Inc.	1-Piperidine-alkylene ketones, pharmaceutical compositions thereof and method of use thereof
US4254129A (en) *	1979-04-10	1981-03-03	Richardson-Merrell Inc.	Piperidine derivatives
US4254130A (en) *	1979-04-10	1981-03-03	Richardson-Merrell Inc.	Piperidine derivatives
EP0111114A3 (de) *	1982-11-06	1985-10-09	Telefonbau und Normalzeit GmbH	Schaltungsanordnung für eine Fernsprechvermittlungsanlage, insbesondere Fernsprechnebenstellenanlage mit zusätzlichem Datenverkehr
GB8613811D0 (en) *	1986-06-06	1986-07-09	Phares Pharm Res Nv	Composition & method
US4609675A (en) *	1984-08-17	1986-09-02	The Upjohn Company	Stable, high dose, high bulk density ibuprofen granulations for tablet and capsule manufacturing
DK164642C (da) *	1984-08-30	1992-12-14	Merrell Dow Pharma	Farmaceutisk middel indeholdende terfenadin i form af en varmsmelte paafyldt paa kapsler
US4639458A (en) *	1985-01-22	1987-01-27	Merck & Co., Inc.	Tablet and formulation
US4916163A (en) *	1985-06-04	1990-04-10	The Upjohn Company	Spray-dried lactose formulation of micronized glyburide
SE457326B (sv) *	1986-02-14	1988-12-19	Lejus Medical Ab	Foerfarande foer framstaellning av en snabbt soenderfallande kaerna innehaallande bl a mikrokristallin cellulosa
US4963540A (en) *	1986-04-16	1990-10-16	Maxson Wayne S	Method for treatment of premenstrual syndrome
SE8603812D0 (sv) *	1986-09-12	1986-09-12	Draco Ab	Administration of liposomes to mammals
DE3720493A1 (de) *	1987-06-20	1989-01-26	Nattermann A & Cie	Arzneizubereitungen mit mikronisierten ebselen-kristallen
CN1053570C (zh) *	1987-10-07	2000-06-21	默尔多药物公司	哌啶子基链烷醇的药用组合物-减充血剂复方的制备方法
US4996061A (en) *	1987-10-07	1991-02-26	Merrell Dow Pharmaceuticals Inc.	Pharmaceutical composition for piperidinoalkanol-decongestant combination
AR240018A1 (es) *	1987-10-07	1990-01-31	Merrell Pharma Inc	Procedimiento para preparar una composicion que comprende derivados de piperidinoalcanol.
US4929605A (en) *	1987-10-07	1990-05-29	Merrell Dow Pharmaceuticals Inc.	Pharmaceutical composition for piperidinoalkanol derivatives
JPH0196920A (ja) *	1987-10-09	1989-04-14	Fujitsu Ltd	ウエーハの識別方法
US4999226A (en) *	1988-06-01	1991-03-12	Merrell Dow Pharmaceuticals Inc.	Pharmaceutical compositions for piperidinoalkanol-ibuprofen combination
AR245888A1 (es) *	1989-01-23	1994-03-30	Merrell Pharma Inc	Procedimiento para la preparacion de una composicion farmaceutica liquida de derivados de piperidinoalcanol.
US4990535A (en) *	1989-05-03	1991-02-05	Schering Corporation	Pharmaceutical composition comprising loratadine, ibuprofen and pseudoephedrine
US5376386A (en) *	1990-01-24	1994-12-27	British Technology Group Limited	Aerosol carriers
IT1246188B (it) *	1990-07-27	1994-11-16	Resa Farma	Procedimento per la preparazione di composizioni farmaceutiche aventi aumentata velocita' di dissoluzione della sostanza attiva e composizioni ottenute.
US5271944A (en) *	1991-04-05	1993-12-21	Biofor, Ltd.	Pharmacologically enhanced formulations
SE9101090D0 (sv) *	1991-04-11	1991-04-11	Astra Ab	Process for conditioning of water-soluble substances
IT1250421B (it) *	1991-05-30	1995-04-07	Recordati Chem Pharm	Composizione farmaceutica a rilascio controllato con proprieta' bio-adesive.
US5169638A (en) *	1991-10-23	1992-12-08	E. R. Squibb & Sons, Inc.	Buoyant controlled release powder formulation
US5516803A (en) *	1991-10-30	1996-05-14	Mcneilab, Inc.	Composition comprising a tramadol material and a non-steroidal anti-inflammatory drug
WO1993011744A1 (en) *	1991-12-12	1993-06-24	Glaxo Group Limited	Medicaments
US5301664A (en) *	1992-03-06	1994-04-12	Sievers Robert E	Methods and apparatus for drug delivery using supercritical solutions
WO1993023047A1 (en) *	1992-05-11	1993-11-25	Merrell Dow Pharmaceuticals Inc.	Use of terfenadine derivatives as antihistaminics in a hepatically impaired patient
US5429825A (en) *	1992-06-26	1995-07-04	Mcneil-Ppc, Inc.	Rotomelt granulation
FI950467A7 (fi) *	1992-08-03	1995-03-31	Sepracor Inc	Terfenadiinin metaboliitit ja niiden optisesti puhtaat isomeerit aller gisten sairauksien hoitamiseksi
US5474757A (en) *	1992-10-16	1995-12-12	Rutgers University	Prevention of acetaminophen overdose toxicity with organosulfur compounds
US5314697A (en) *	1992-10-23	1994-05-24	Schering Corporation	Stable extended release oral dosage composition comprising loratadine and pseudoephedrine
SE9203743D0 (sv) *	1992-12-11	1992-12-11	Astra Ab	Efficient use
IT1264517B1 (it) *	1993-05-31	1996-09-24	Ekita Investments Nv	Compressa farmaceutica atta al rilascio in tempi successivi dei principi attivi in essa veicolati
HU226559B1 (en) *	1993-06-24	2009-03-30	Amr Technology	Process for the production of piperidine derivatives
IT1264696B1 (it) *	1993-07-09	1996-10-04	Applied Pharma Res	Forme farmaceutiche destinate alla somministrazione orale in grado di rilasciare sostanze attive a velocita' controllata e differenziata
CA2128820A1 (en) *	1993-07-27	1995-01-28	Walter G. Gowan, Jr.	Rapidly disintegrating pharmaceutical dosage form and process for preparation thereof
CA2128821A1 (en) *	1993-07-27	1995-01-28	Dilip J. Gole	Freeze-dried pharmaceutical dosage form and process for separation thereof
US5895664A (en) *	1993-09-10	1999-04-20	Fuisz Technologies Ltd.	Process for forming quickly dispersing comestible unit and product therefrom
WO1995010278A1 (en) *	1993-10-15	1995-04-20	Hoechst Marion Roussel, Inc.	Treatment of allergic disorders with terfenadine carboxylate
US5451409A (en) *	1993-11-22	1995-09-19	Rencher; William F.	Sustained release matrix system using hydroxyethyl cellulose and hydroxypropyl cellulose polymer blends
US5478858A (en) *	1993-12-17	1995-12-26	The Procter & Gamble Company	5-(2-imidazolinylamino) benzimidazole compounds useful as alpha-2 adrenoceptor agonists
US5458879A (en) *	1994-03-03	1995-10-17	The Procter & Gamble Company	Oral vehicle compositions
CA2449419C (en) *	1994-05-18	2011-09-06	Aventis Pharmaceuticals Inc.	Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudomorphs thereof
US5567439A (en) *	1994-06-14	1996-10-22	Fuisz Technologies Ltd.	Delivery of controlled-release systems(s)
EP0812195B1 (en) *	1995-02-28	2002-10-30	Aventis Pharmaceuticals Inc.	Pharmaceutical composition for piperidinoalkanol compounds
US5574045A (en) *	1995-06-06	1996-11-12	Hoechst Marion Roussel, Inc.	Oral pharmaceutical composition of piperidinoalkanol compounds in solution form
SK20099A3 (en) *	1996-08-16	2000-08-14	Schering Corp	Treatment of upper airway allergic responses with a combination of histamine receptor antagonists
JPH10114655A (ja) *	1996-10-09	1998-05-06	Kyowa Hakko Kogyo Co Ltd	固形製剤
US5837379A (en) *	1997-01-31	1998-11-17	Andrx Pharmaceuticals, Inc.	Once daily pharmaceutical tablet having a unitary core
GB9707934D0 (en) *	1997-04-18	1997-06-04	Danbiosyst Uk	Improved delivery of drugs to mucosal surfaces
CA2281789A1 (en) *	1997-04-30	1998-11-05	Warner-Lambert Company	Topical nasal antiinflammatory compositions
DE19720312A1 (de) *	1997-05-15	1998-11-19	Hoechst Ag	Zubereitung mit erhöhter in vivo Verträglichkeit
PT1003476E (pt) *	1997-08-11	2005-05-31	Alza Corp	Forma de dosagem de agente activo de libertacao prolongada adaptada para retencao gastrica
US5869479A (en) *	1997-08-14	1999-02-09	Schering Corporation	Treatment of upper airway allergic responses
JP4295913B2 (ja) *	1997-08-14	2009-07-15	アベンティス・ファーマスーティカルズ・インコーポレイテツド	フェキソフェナジンおよびその誘導体のバイオアベイラビリティーを強化する方法

1998
- 1998-07-21 NZ NZ501248A patent/NZ501248A/en not_active IP Right Cessation
- 1998-07-21 RU RU99125326/14A patent/RU2207879C2/ru active
- 1998-07-21 IL IL13342098A patent/IL133420A/en not_active IP Right Cessation
- 1998-07-21 CN CNB988085275A patent/CN1159012C/zh not_active Expired - Lifetime
- 1998-07-21 KR KR10-1999-7011550A patent/KR100514264B1/ko not_active Expired - Lifetime
- 1998-07-21 PL PL337348A patent/PL192079B1/pl unknown
- 1998-07-21 TR TR2000/00517T patent/TR200000517T2/xx unknown
- 1998-07-21 ES ES98937010T patent/ES2192781T3/es not_active Expired - Lifetime
- 1998-07-21 BR BR9812001-8A patent/BR9812001A/pt not_active IP Right Cessation
- 1998-07-21 HU HU0002183A patent/HU224921B1/hu unknown
- 1998-07-21 DE DE69814086T patent/DE69814086T2/de not_active Expired - Lifetime
- 1998-07-21 JP JP51430099A patent/JP4344405B2/ja not_active Expired - Lifetime
- 1998-07-21 CZ CZ19994581A patent/CZ295461B6/cs not_active IP Right Cessation
- 1998-07-21 PT PT98937010T patent/PT998272E/pt unknown
- 1998-07-21 SK SK1777-99A patent/SK283803B6/sk not_active IP Right Cessation
- 1998-07-21 AU AU85820/98A patent/AU725811B2/en not_active Expired
- 1998-07-21 WO PCT/US1998/015237 patent/WO1999009957A1/en not_active Ceased
- 1998-07-21 UA UA99126576A patent/UA60335C2/uk unknown
- 1998-07-21 SI SI9830454T patent/SI0998272T1/xx unknown
- 1998-07-21 DK DK98937010T patent/DK0998272T3/da active
- 1998-07-21 EP EP98937010A patent/EP0998272B1/en not_active Expired - Lifetime
- 1998-07-21 EE EEP200000098A patent/EE04294B1/xx unknown
- 1998-07-21 AT AT98937010T patent/ATE238773T1/de active
- 1998-07-21 ID IDW991512A patent/ID22891A/id unknown
- 1998-07-31 US US09/127,478 patent/US6039974A/en not_active Expired - Lifetime
- 1998-08-20 ZA ZA987552A patent/ZA987552B/xx unknown
- 1998-08-21 TW TW087113848A patent/TW570812B/zh not_active IP Right Cessation
- 1998-08-25 AR ARP980104196A patent/AR013947A1/es not_active Application Discontinuation
2000
- 2000-02-04 OA OA1200000029A patent/OA11285A/en unknown
- 2000-02-25 NO NO20000932A patent/NO318246B1/no not_active IP Right Cessation

Also Published As

Publication number	Publication date
CZ295461B6 (cs)	2005-08-17
ZA987552B (en)	1999-02-26
WO1999009957A1 (en)	1999-03-04
EE200000098A (et)	2000-12-15
CZ458199A3 (cs)	2000-05-17
TW570812B (en)	2004-01-11
AR013947A1 (es)	2001-01-31
DE69814086D1 (de)	2003-06-05
OA11285A (en)	2003-07-29
AU8582098A (en)	1999-03-16
PL337348A1 (en)	2000-08-14
ES2192781T3 (es)	2003-10-16
SK283803B6 (sk)	2004-02-03
JP4344405B2 (ja)	2009-10-14
DE69814086T2 (de)	2004-04-08
NO318246B1 (no)	2005-02-21
BR9812001A (pt)	2000-09-26
CN1159012C (zh)	2004-07-28
EP0998272A1 (en)	2000-05-10
KR20010013543A (ko)	2001-02-26
SK177799A3 (en)	2000-07-11
PL192079B1 (pl)	2006-08-31
EP0998272B1 (en)	2003-05-02
AU725811B2 (en)	2000-10-19
EE04294B1 (et)	2004-06-15
TR200000517T2 (tr)	2000-08-21
JP2002511102A (ja)	2002-04-09
SI0998272T1 (en)	2003-12-31
HUP0002183A3 (en)	2000-12-28
KR100514264B1 (ko)	2005-09-15
ID22891A (id)	1999-12-16
DK0998272T3 (da)	2003-08-25
NO20000932L (no)	2000-04-18
US6039974A (en)	2000-03-21
ATE238773T1 (de)	2003-05-15
NO20000932D0 (no)	2000-02-25
HK1025904A1 (en)	2000-12-01
HU224921B1 (hu)	2006-04-28
CN1268050A (zh)	2000-09-27
UA60335C2 (uk)	2003-10-15
PT998272E (pt)	2003-09-30
IL133420A0 (en)	2001-04-30
RU2207879C2 (ru)	2003-07-10
NZ501248A (en)	2001-06-29
HUP0002183A2 (hu)	2000-11-28

Legal Events

Date	Code	Title
2004-12-15	FF	Patent granted
2005-02-20	KB	Patent renewed
2005-05-17	KB	Patent renewed
2008-12-29	KB	Patent renewed
2012-07-31	KB	Patent renewed
2016-06-30	KB	Patent renewed
2019-02-28	EXP	Patent expired

Publication	Publication Date	Title
EP0998272B1 (en)	2003-05-02	Pharmaceutical composition for combination of piperidinoalkanol-decongestant
JP5158919B2 (ja)	2013-03-06	延長放出経口用量組成物
FI90205B (fi)	1993-09-30	Menetelmä piperidinoalkanoli-ibuprofeeniyhdistelmää sisältävän farmaseuttisen koostumuksen valmistamiseksi
KR20010062542A (ko)	2001-07-07	안정한 서방출형의 경구 투여용 조성물
EP2356985A1 (en)	2011-08-17	Novel pharmaceutical compositions comprising a combination of metformin and sitagliptin
WO2009149056A2 (en)	2009-12-10	Combinations of niacin and an oxicam
NZ530289A (en)	2004-11-26	Pharmaceutical composition comprising cetirizine and pseudoephedrine that contains less than 5% or no alkalinising agent
AU2002345024A1 (en)	2003-05-15	Tablet comprising cetirizine and pseudoephedrine
HK1025904B (en)	2003-09-05	Pharmaceutical composition for combination of piperidinoalkanol-decongestant
MXPA99011699A (en)	2000-05-01	Pharmaceutical composition for combination of piperidinoalkanol-decongestant
EP1569651B1 (en)	2008-07-30	Tablet comprising efletirizine and pseudoephedrine
US20070099931A1 (en)	2007-05-03	Pharmaceutical dosage forms and compositions
KR100523242B1 (ko)	2005-10-24	이부프로펜을 함유하는 정제 조성물
CA2620491A1 (en)	2007-03-15	Pharmaceutical dosage forms and compositions comprising lecoztan
Center et al.	0	2) Patent Application Publication o Pub. No.: US 2021/0161863 A1
KR20090125660A (ko)	2009-12-07	새로운 나이아신 및 ＨＭＧ-ＣｏＡ 환원 효소 억제제 복합제제